**PvGAMA reticulocyte binding activity: predicting conserved functional regions by natural selection analysis**

Luis A. Baquero¹, Darwin A. Moreno-Pérez¹,²†, Diego Garzón-Ospina¹,², Johanna Forero-Rodríguez¹, Heidy D. Ortiz-Suárez¹ and Manuel A. Patarroyo¹,³*

**Abstract**

**Background:** Adhesin proteins are used by *Plasmodium* parasites to bind and invade target cells. Hence, characterising molecules that participate in reticulocyte interaction is key to understanding the molecular basis of *Plasmodium vivax* invasion. This study focused on predicting functionally restricted regions of the *P. vivax* GPI-anchored micronemal antigen (PvGAMA) and characterising their reticulocyte binding activity.

**Results:** The *pvgama* gene was initially found in *P. vivax* VCG-I strain schizonts. According to the genetic diversity analysis, PvGAMA displayed a size polymorphism very common for antigenic *P. vivax* proteins. Two regions along the antigen sequence were highly conserved among species, having a negative natural selection signal. Interestingly, these regions revealed a functional role regarding preferential target cell adhesion.

**Conclusions:** To our knowledge, this study describes PvGAMA reticulocyte binding properties for the first time. Conserved functional regions were predicted according to natural selection analysis and their binding ability was confirmed. These findings support the notion that PvGAMA may have an important role in *P. vivax* merozoite adhesion to its target cells.

**Keywords:** Adhesin protein, *Plasmodium vivax*, Genetic diversity, Conserved functional region, Reticulocyte binding activity

**Background**

*Plasmodium vivax* is a human malaria-causing parasite whose eradication is a priority on the international health agenda [1]. As a strategy for eradicating this species, several research groups have focused their efforts on developing a vaccine, as vaccination has been successful at controlling and eradicating other infectious diseases [2].

It has been suggested that vaccines should consist of key proteins or their fragments used by infectious agents to bind to the target cells [3, 4]. Hence, knowledge of proteins expressed by the parasite at the end of its intra-erythrocyte life-cycle, especially those interacting with red blood cells (RBC), should prove most suitable as candidate vaccine components.

Current efforts to develop an anti-malarial vaccine have mainly focused on *P. falciparum*, given the availability of robust in vitro culturing techniques for this parasite (currently unavailable for *P. vivax*) which has led to a large-scale identification of genes [5], transcripts [6] and proteins [7]. This information has led to an improved understanding of the molecules involved in *P. falciparum* merozoite invasion of erythrocytes. For example, several adhesin molecules have been described in the apical organelles (rhoptries and micronemes), that facilitate interaction with cell receptors and promote parasite internalisation within the target cell [8]. Several of these proteins are immunogenic and are being evaluated as vaccine candidates in clinical studies [9]. The GPI-anchored micronemal antigen (GAMA) represents one apical protein that has an adhesive role in *Plasmodium* and *Toxoplasma*. *Plasmodium falciparum* GAMA (PfGAMA) binds to human erythrocytes, an interaction...
mediated by its binding region which is located in the amino terminal sequence, and is involved in the sialic acid-independent invasion pathway [10]. On the other hand, GAMA knockouts of T. gondii (TgGAMA) show a reduction in the ability of tachyzoites to attach to the host cell during invasion as well as a delay in the time to death in an in vivo model, suggesting a function during parasite adhesion and invasion [11].

Unfortunately, basic P. vivax research has been delayed mainly due to the parasite’s preference for invading reticulocytes which are difficult to obtain in the high percentages needed for propagating P. vivax in vitro [12, 13]. However, it has been possible to characterise several molecules forming part of the parasite’s selective human reticulocyte invasion route, such as reticulocyte binding proteins (RBPs) [14, 15], merozoite surface protein 1 (MSP-1) [16], some proteins from the tryptophan-rich antigen (TRAG) family [17] and the recently described rhoptry neck protein 5 (RON5) [18]. Some of these contain specific binding regions that have been identified using several strategies, such as mapping using peptides labelled with radioactive iodine, ELISA, flow cytometry or rosetting assays. However, these methodologies are laborious when large molecules must be analysed. Furthermore, sometimes it is not known whether these regions are polymorphic between isolates, which would be counterproductive for the development of a broadly protective vaccine.

A new strategy has recently been proposed for identifying selection signals and that enables the determination of conserved antigens or those having potential functional regions [19]. Cornejo et al. [20] and Garzón-Ospina et al. [19] identified natural selection signals in P. vivax genes when analysing the sequences of five genomes from different locations [21]. These results were supported by earlier studies, increasing the number of sequences analysed [22–24]. This type of analysis could therefore provide a viable approach for selecting conserved antigens that are subject to functional restrictions. However, no experimental evidence has been produced to support such approach.

Given the importance of conserved functional region prediction and the role of adhesin proteins during host-parasite interaction, and considering the interesting features displayed by GAMA in other apicomplexa, the present study aimed at characterising P. vivax VCG-I strain GAMA functional regions by selection signal prediction and then determine the role of such regions in binding to reticulocytes.

Methods
An approach to GAMA genetic diversity and evolutionary forces
Evolutionary methods compare the non-synonymous mutations rate (d_N, mutations altering protein sequences) to the synonymous mutations rate (d_S, those encoding the same amino acid) in the search for natural selection signals. Deleterious mutations are usually removed from populations by negative natural selection (d_N < d_S or \( \omega < 1 \)). Regions displaying this kind of selection might have functional/structural importance, maintaining high sequence conservation between species [25]. On the other hand, mutations having an adaptive advantage (or a beneficial role) are fixed in a population by positive natural selection (d_N > d_S or \( \omega > 1 \)). Taking the above into account, functional regions could be predicted by evolutionary approaches [19], pgama gene DNA sequences from 6 P. vivax strains (VCG-I, Sal-I, Brazil-I, India-VII, Mauritania-I and North Korea [21]) and 5 phylogenetically-related species (P. cynomolgi, P. inui, P. fragile, P. knowlesi and P. coatneyi) [26] were obtained by tblastn (except for VCG-I) from the whole-genome shotgun contigs (wgs) NCBI database for assessing genetic diversity and evolutionary forces regarding GAMA. The MUSCLE algorithm [27] was used to align the sequences and the alignment was manually corrected. Nucleotide diversity per site (n) was estimated from the P. vivax sequences and the modified Nei-Gojobori method [28] was used to assess natural selection signals by calculating the difference between synonymous and non-synonymous substitution rates (d_N–d_S). Natural selection was also assessed by estimating the difference between synonymous and non-synonymous divergence rates (K_N–K_S) using sequences from P. vivax and related species through the modified Nei-Gojobori method and Jukes-Cantor correction [29]. Specific codons under natural selection amongst species were identified using codon-based Bayesian or maximum likelihood approaches (SLAC, FEL, REL [30], MEME [31] and FUBAR [32]), following recombination by the GARD method [33]. Codon-based methods estimate the evolutionary rate (\( \omega \)) at each codon using a statistical test to determine whether \( \omega \) is significantly different from 1 (neutral evolution). The Branch-site REL algorithm [34] was used to identify lineages under episodic positive selection (selection occasionally having transient periods of adaptive evolution masked by negative selection or neutral evolution). The Datamonkey web server was used to perform these analyses [35].

Primer design, cloning and sequencing
The Plasmodium vivax gama (pgama) gene sequence was taken from the PlasmoDB database [36] and scanned for PCR priming sites (Table 1) using Generunner software (version 3.05). Primers were designed to amplify either the entire pgama gene or several smaller-sized fragments according to the natural selection analysis (Fig. 1). The gDNA (extracted using a Wizard Genomic purification kit; Promega, Madison, USA) and cDNA (synthesised with SuperScript III enzyme (RT+) (Invitrogen,
Carlsbad, USA) samples from *P. vivax* VCG-I strain schizont-stage enriched parasites (propagated and obtained as previously described [37, 38]) were used as template in 25 μl PCR reactions containing 1× KAPA HiFi HotStart ReadyMix (KAPA Biosystems, Woburn, MA, USA), 0.3 μM primers and DNAse-free water. Temperature cycling for PCR involved a denaturing step of 95 °C for 5 min, followed by 35 cycles of 98 °C for 20 s, Tm °C (Table 1) for 15 s and 72 °C for 30 s or 1 min and 30 s depending on product size. A Wizard PCR preps kit (Promega) was used for purifying amplicons obtained from PCR with the RT+ and gDNA samples, once quality had been evaluated on agarose gel. Purified products were ligated to the pEXP5 CT/TOPO expression vector or pGEM (Promega) (for the gene obtained from gDNA) and transformed in TOP10 *E. coli* cells (Invitrogen). Several clones obtained from independent PCR reactions were grown for purifying the plasmid using an UltraClean mini plasmid prep purification kit (MO BIO Laboratories, California, USA). Insert integrity and correct orientation were then confirmed by sequencing, using an ABI-3730 XL sequencer (MACROGEN, Seoul, South Korea). ClustalW (NPS@) software was used for comparing gene sequences from Sal-I reference strain and the primate-adapted VCG-I strain [39]. The *pvgama* gene sequence from *P. vivax* VCG-I strain was deposited in NCBI under accession number KT248546.

**Recombinant protein expression**

The pEXP-*pvgama* recombinant plasmids were transformed in *E. coli* BL21-DE3 (Invitrogen), according to the manufacturer’s recommendations. Cells were grown

### Table 1 Primer designed for *pvgama* gene amplification

| Target       | Primer sequence (5’–3’) | MT (°C) | Product size (bp) | aa position |
|--------------|-------------------------|---------|-------------------|-------------|
| *pvgama*     | Fwd: ATGAAGTGCAACGCCTCC  | 58      | 2313              | 1 to 771    |
|              | Rev: AAAATGAATAGGAGCAACG |         |                   |             |
| *pvgama* -Nt | Fwd: ATACGGAAATGGAACAACC | 1284    | 22 to 449         |             |
|              | Rev: AGTGGTCTGGTATTCG    |         |                   |             |
| *pvgama* -Ct | Fwd: CTGCTCAAGAAGACAGAAC | 948     | 434 to 749        |             |
|              | Rev: GCTCCACCTGCAATTCC   |         |                   |             |
| *pvgama* -CR1| Fwd: GACGATCATCTCTGTTCAAAA | 60      | 666               | 87 to 308   |
|              | Rev: GACCTCAATTTGGACCTTC  |         |                   |             |
| *pvgama* -VR1| Fwd: GGCCTCTCTGTCAGTC    | 438     | 330 to 475        |             |
|              | Rev: CATTTACATGTTCTGC    |         |                   |             |
| *pvgama* -CR2| Fwd: CAGGCGCCCATCTCTAA   | 321     | 482 to 588        |             |
|              | Rev: GCTCCGTTGACCCCTT    |         |                   |             |
| *pvgama* -VR2| Fwd: GCCGCAAACGCAGACGCC  | 384     | 626 to 753        |             |
|              | Rev: GITTGGCGAGAACCTTCAC |         |                   |             |

**Abbreviations:** Nt and Ct amino and carboxyl terminal; CR conserved region, VR variable region; Fwd forward, Rev reverse, MT melting temperature, bp base pair, aa amino acid

*Protein’s expression start codon was included in forward primer’s 5’ end

**Fig. 1** Evolutionary rate (ω) sliding window. Intra-species ω values (dN/dS) are represented in blue whilst inter-species ω values (K_N/K_S between *P. vivax* and malarial parasites infecting primates) are shown in purple. A ω value equal 1 means neutral evolution, ω < 1 negative selection whilst ω > 1 means positive selection. A diagram of the gene can be observed below the sliding window. Negatively selected inter-species codons are shown in green whilst positively selected sites are shown in red. Numbering is based on the alignment in Additional file 1: Figure S1.
overnight at 37 °C in 50 ml Luria Bertani (LB) medium containing 100 μg/ml ampicillin using a Lab-line Incubator Shaker. The initial inoculum was then seeded in 1 l of LB with ampicillin (100 μg/ml) and left to grow at 37 °C with shaking at ~300× rpm until reaching 0.5 OD600. The culture was incubated on ice for 30 min and then IPTG 1 mM was used to induce expression by incubation for 16 h at room temperature (RT) with shaking at ~200× rpm. The culture was then spun at 2400× g for 20 min and the pellet was collected for extraction of the recombinant protein.

**Denaturing extraction**

The cell pellet obtained from *E. coli* expressing *PvGAMA-Nt* and *PvGAMA-Ct* fragments was homogenised in denaturing extraction buffer (DEB) (6 M urea, 10 mM Tris, 100 mM NaH2PO4 and 20 mM imidazole) containing the SIGMAFAST protease inhibitor cocktail (Sigma-Aldrich, St. Louis, USA) and then lysed by incubating with 0.1 mg/ml lysozyme overnight at 4 °C at 10× rpm using a tube rotator (Fisher Scientific, Waltham, USA). The supernatant was collected by spinning at 16,000× g for 1 h.

**Native extraction**

*PvGAMA-CR1, PvGAMA-VR1, PvGAMA-CR2* and *PvGAMA-VR2* were extracted using a method for obtaining the molecules in native conditions with the respective positive and negative controls (region II and III/IV from the Duffy binding protein, DBP) (unpublished data). Briefly, the pellet was frozen/thawed for 3 cycles and then homogenised in native extraction buffer (NEB) (50 mM Tris, 300 mM NaCl, 25 mM imidazole, 0.1 mM EGTA and 0.25% Tween-20, pH 8.0). The mixture was incubated for 1 h at 4 °C at 10× rpm and the supernatant was collected by spinning at 16,000× g for 1 h.

**Protein purification**

Total lysate supernatant was incubated with Ni2+-NTA resin (Qiagen, Valencia, CA, USA) for purifying the proteins by solid-phase affinity chromatography, once protein expression had been verified by western blot. Briefly, the resin was pre-equilibrated with the respective buffer used for extracting proteins and then incubated with the *E. coli* lysate overnight at 4 °C. The protein-resin mixture was placed on a column and then weakly bound proteins were eluted by washing with 20 ml buffer containing 0.1% Triton X-114 followed by 50 ml of the same buffer without detergent. The proteins extracted in denaturing conditions were dialysed on the column by passing 20 ml DEB with urea in descending concentrations (6 M, 3 M, 1.5 M, 0.75 M and PBS). Bound proteins were then eluted with PBS containing imidazole at increasing concentrations (50 mM to 500 mM) in 3 ml fractions; those having a single band (confirmed on 12% SDS-PAGE by Coomassie blue staining and by western blot using anti-polyhistidine antibodies) were pooled and dialysed extensively in PBS, pH 7.2. A micro BCA protein assay kit (Thermo Scientific, Rockford, USA) was used for quantifying each protein, using the bovine serum albumin (BSA) curve as reference.

**Peptide synthesis**

One 6 histidine peptide was synthesised according to a previously-established methodology [40], polymerised, lyophilised and characterised by RP-HPLC and MALDI-TOF MS. The peptide was homogenised in PBS and then stored at -20 °C until use.

**Blood sample collection and processing**

Individuals with a clinical history of *P. vivax* (37 subjects) or *P. falciparum* (30 subjects) malaria, aged 18 to 50 year-old and living in malaria-endemic areas of Colombia (Chocó, Nariño, Córdoba, Vichada and Guaviare) were selected for this study. Sera from healthy individuals (16 adult subjects) who had never been affected by the disease and who were living in non-endemic areas were used as negative controls. The blood samples were collected in BD Vacutainer tubes without anticoagulant by personnel from the Fundación Instituto de Inmunología de Colombia (FIDIC) from October 2006 to March 2011 (for *P. vivax*) and June to October 1993 (for *P. falciparum*) and stored at 4 °C until transport. Samples were then transported to Bogotá for processing. Total blood was spun at 5000× g for 5 min and the serum was then recovered and stored at -80 °C in FIDIC serum bank (to date).

**Enzyme-linked immunosorbent assay (ELISA)**

*PvGAMA* antigenicity was evaluated in triplicate using serum from patients who had suffered episodes of *P. vivax* or *P. falciparum* infection. Briefly, 96-well polystyrene plates were covered with 1 μg *rPvGAMA-Nt*, or *rPvGAMA-Ct*, overnight at 4 °C and then incubated at 37 °C for 1 h. The dishes were blocked with 200 μl 5% skimmed milk - PBS-0.05% Tween for 1 h at 37 °C. Antibody reactivity against the recombinant protein was evaluated by incubating the plates with 1:100 dilution of each human serum in 5% skimmed milk - PBS-0.05% Tween for 1 h at 37 °C. Antibody reactivity against the recombinant protein was evaluated by incubating the plates with 1:100 dilution of each human serum in 5% skimmed milk - PBS-0.05% Tween for 1 h at 37 °C. Antibody reactivity against the recombinant protein was evaluated by incubating the plates with 1:100 dilution of each human serum in 5% skimmed milk - PBS-0.05% Tween for 1 h at 37 °C and then a peroxidase substrate solution (KPL Laboratories, Gaithersburg, MD, USA) was added to reveal the reaction, according to the manufacturer’s recommendations. Optical density (OD) at 620 nm (detected by MJ ELISA Multiskian Reader) was
calculated by subtracting the OD value obtained from the control well value (no antigen). The cut-off value for evaluating the positivity threshold was determined by taking the average of the OD plus twice the standard deviation (± 2SD) of healthy individuals’ sera reactivity.

**Cord blood sample processing**
The newborn umbilical cord blood samples used in this research were collected by personnel from the Hemo-centro Distrital (Bogotá) and then processed by SEPAX Cell Processing System (Biosafe, Eysins, Switzerland) to reduce nucleated cells, according to the manufacturer’s recommendations. The samples were stored at 4 °C and Duffy antigen receptor for chemokines (DARC) presence was determined by agglutination assay using antibodies directed against the molecule’s Fya or Fyb fraction. The percentage of nucleated cells was scored in 20 fields at 100× magnification using Wright’s stain before carrying out the binding assay.

**Cell binding assay**
Reticulocyte binding was tested in triplicate by flow cytometry and using the total cells from cord blood sample (Fya−Fyb+ phenotype). Briefly, 5 μl samples were incubated with 25 μg of each recombinant protein (PvGAMA-CR1, PavGAMA-CR2, PrGAMA-CR2 and PrGAMA-VR2) for 16 h at 4 °C at 4× rpm. Twenty-five μg of DBP region II and III/IV were used as positive and negative controls, respectively. The 6 histidine peptide was also used as control once the recombinant proteins contained a 6-histidine tag. A binding inhibition assay was also performed by incubating PrGAMA conserved recombinant proteins (CR1 and CR2) with a mixture of human sera (1:10 dilution) for 1 h at 4 °C before putting them in contact with cells. The samples were then incubated with mouse anti-His-PE monoclonal antibody (1:40 dilution) (MACS molecular-Miltenyi Biotec, San Diego, CA, USA) for 30 min in the dark after washing with 1% BSA-PBS solution (v/v). White cells and reticulocytes were stained by incubating with anti-CD45 APC clone 2D1 (1:80 dilution) (Becton Dickinson, Franklin Lakes, NJ, USA) and anti-CD71 APC-H7 clone M-A712 (1:80 dilution) (Becton Dickinson) monoclonal antibodies for 20 min at RT. Subsequently, reticulocyte (CD71 + CD45-PE+) and mature erythrocyte (CD71-CD45-PE+) binding was quantified by analysing 1 million events using a FACSCanto II cytometer (BD, San Diego, CA, USA) and Flowjo V10 software. PE signal intensity in the reticulocyte population was evaluated regarding CD71 signal to determine CD71 low (CD71<sup>lo</sup>) and high (CD71<sup>hi</sup>) cells.

**Statistical analysis**
Mean values and standard deviations (SD) were calculated from the measurements of three independent experiments. Statistical significance was assessed by comparing means using a 0.05 significance level for testing a stated hypothesis. Student’s t-test and analysis of variance (ANOVA) were used for comparing the means of each experimental group to those for control. Tukey’s multiple comparison test was used for multiple comparison of experimental group means to those for control. GradPad Software (San Diego, CA) was used for all statistical analysis.

**Results**

**PvGAMA genetic diversity and selection signals**
Pv-gama sequences were obtained from genomes of 5 different strains from different geographical regions (North Korea, Brazil, Mauritania and India). These were aligned with the VCG-I strain sequence and orthologous sequences from 5 phylogenetically-related species. The alignment revealed a size polymorphism in pgama due to the [C/T][G/C][C/A/T][A/A/C/T][G/G][A/G/C][G/A][AC/G/C/A] repeat which was not present in P. cynomolgi, P. inui, P. fragile, P. knowlesi or P. coatneyi (Additional file 1: Figure S1). Regarding P. vivax, 5 segregating sites and π = 0.0008 were observed.

No significant values were found when evaluating synonymous and non-synonymous substitution rates (dN−dS = -0.001 (0.001), P > 0.1). However, synonymous divergence was greater than non-synonymous divergence (P < 0.0001) when comparing pgama sequences to each related species: NS-KS P. vivax/P. cynomolgi = -0.041 (0.006); NS-KS P. vivax/P. inui = -0.062 (0.008); NS-KS P. vivax/P. fragil = -0.030 (0.006); NS-KS P. vivax/P. knowlesi = -0.072 (0.009); NS-KS P. vivax/P. coatneyi = -0.049 (0.007). The evolutionary rate ω (dN/dS and KN/KS) sliding window showed that two highly conserved regions amongst species (codons 80–320 and 514–624) might be under negative selection (<0.5). Furthermore, 308 negatively-selected codons were observed amongst species (Fig. 1); a lot of them were in the conserved regions. The Branch-site REL algorithm identified episodic positive selection signals in the lineages giving rise to P. knowlesi and P. coatneyi as well as the lineage formed by P. cynomolgi and P. fragile (Additional file 2: Figure S2). 22 sites showed evidence of positive selection amongst species (Fig. 1).

**Antigenic response was directed against the GAMA carboxyl fragment**
Based on the polymorphism analysis results, it was hypothesised that the carboxyl region was more antigenic than the amino one by the presence of the repetitive region. Hence, rPvGAMA-Nt and rPvGAMA-Ct antigenicity (obtained recombinantly; Additional file 3: Figure S3a, b) was evaluated using sera from 37 patients suffering of P. vivax malaria and sera from people who had never suffered the disease. rPvGAMA-Nt reacted
positively with 64.8% of the sera in screening (0.26 cut-off point) whilst 67.5% of them recognised rPvGAMA-Ct (0.47 cut-off point). These data agreed with a study of the profile of the humoral immune response for *P. vivax* in which rPvGAMA was recognised by 54.5% of the sera used in the array [41]. The statistical test for the assay with rPvGAMA-Nt gave a significant difference between the means (m) of the groups (ANOVA: F(1,41) = 4.73, P = 0.035; m = 0.38 for the group of infected patients and m = 0.12 for the control group). Likewise, there was a significant difference between the means of the groups (ANOVA: F(1,41) = 14.75, P = 0.0001; m = 0.67 for the group of infected patients and m = 0.14 for the control group) when rPvGAMA-Ct was detected by human sera (Fig. 2a). There was also a statistically significant difference when analysing the means of recognition for rPvGAMA-Nt and rPvGAMA-Ct (ANOVA: F(1,72) = 16.01, P = 0.0002). Taking into account that the response was higher against P. falciparum, it was decided to confirm whether the antibodies generated during *P. falciparum* natural infection were able to detect this fragment. No significant difference (ANOVA: F(1,38) = 0.036, P = 0.850) was seen for P. vivax natural infection, this being higher and species-specific against the P. falciparum carboxyl region.

**PvGAMA bound to human reticulocytes**

Red blood cell samples having the Fya-Fyb+ phenotype (Duffy +) taken from umbilical cord blood were incubated with conserved (CR1 and CR2) and variable (VR1 and VR2) regions extracted and purified in their soluble form (Additional file 3: Figure S3c), predicted by natural selection analysis and then evaluated by flow cytometry to quantify the protein-cell interaction. The percentage of each recombinant binding to erythrocytes was calculated using the gating strategy described in Additional file 4: Figure S4, which enabled selecting the mature (CD71-CD45-) or immature (CD71 + CD45-) cell population to which a target protein was bound (labelled with anti-His PE antibody). All recombinant proteins had a curve shift when the PE signal was compared to control (cells not incubated with recombinant proteins) in the histogram (Fig. 3). Interestingly, the GAMA fragments bound to reticulocytes to a much higher percentage compared to mature erythrocytes (CR1: t-test: t(4) = 24.9, P < 0.0001; VR1: t-test: t(4) = 9.02, P = 0.001; CR2: t-test: t(4) = 12.4, P = 0.0001; VR2: t-test: t(4) = 24.8, P = 0.0001) (Fig. 4a). The conserved regions showed highest interaction with the reticulocytes compared to negative binding controls (ANOVA-Tukey: F(6, 12) = 72.64, P < 0.0001). CR2 recombinant protein bound to 10.11% (SD = 1.33) of target cells, which was very similar to the positive control (m ± SD = 11.8 ± 1.15) (P > 0.189), whilst CR1 were able to bind to 6.36% (SD = 0.30) of the cells (Fig. 4a). Regarding P. vivax variable regions, VR1 was able to bind to 3.08% (SD = 0.54) of the reticulocytes whilst VR2 bound 5.64% (SD = 0.37). CR1, CR2 and VR2 fragments had the highest interaction with CD71HI reticulocytes when binding percentages were analysed as a function of CD71 APC-H7 signal (CR1: t-test: t(4) = 7.32, P = 0.002; CR2: t-test: t(4) = 16.04, P = 0.0001; VR2: t-test: t(4) = 3.71, P = 0.021), unlike VR1 and DBP-RII (VR1: t-test: t(4) = 1.52, P = 0.202; DBP-RII: t-test: t(4) = 0.19, P = 0.853) (as previously found [42]).

---

**Fig. 2** *PvGAMA* antigenicity during natural malaria infection. The dot plot shows OD distribution (Y-axis) for detecting rPvGAMA-Nt or rPvGAMA-Ct by *P. vivax* (a) or rPvGAMA-CT by *P. falciparum* (b) infected (I) and non-infected (NI) patients’ sera (X-axis). rPvGAMA-Nt: infected individuals n = 37, m ± SD = 0.38 ± 0.29; control individuals n = 6, m ± SD = 0.12 ± 0.1. rPvGAMA-Ct: infected individuals n = 37, m ± SD = 0.67 ± 0.32; control individuals n = 6, m ± SD = 0.14 ± 0.08. rPvGAMA-Ct recognised by *P. falciparum* infected patients’ sera: infected individuals n = 30, m ± SD = 0.06 ± 0.04; control individuals n = 10, m ± SD = 0.06 ± 0.03.
These findings suggested that GAMA in *P. vivax* has a functional role in preferential interaction with human reticulocytes.

**Natural antibodies did not affect PvGAMA binding activity**
A cytometry adhesion inhibition assay was performed with sera from individuals suffering *P. vivax* malaria to determine whether the antibodies produced during natural infection could inhibit functional conserved regions (CR1 and CR2) interaction with reticulocytes. Figure 4c shows that conserved recombinant proteins pre-incubated with human sera were able to bind to target cells (CR1: $m \pm SD = 6.21 \pm 0.27$; CR2: $m \pm SD = 9.83 \pm 0.09$), giving a similar percentage to that for controls (CR1: $m \pm SD = 6.5 \pm 0.08$; CR2: $m \pm SD = 10.01 \pm 0.95$) (CR1: *t*-test: $t(3) = 0.55, P = 0.617$; CR2: *t*-test: $t(4) = 0.37, P = 0.730$), suggesting that the immune response was directed against regions which are not implicated in cell binding.

![Flow cytometry analysis](Fig 3 Flow cytometry analysis. Histograms of conserved (a and c) and variable (b and d) GAMA fragments compared to control (cells not incubated with the protein). Each figure is representative from three independent experiments)

![Flow cytometry analysis](Fig 4 *PvGAMA* human reticulocyte binding activity. Flow cytometry analysis showing the recombinant binding percentage to CD71-CD45- and CD71 + CD45- cells (a) and regarding CD71-APCH7 signal (only for CD71 + CD45- cells) (b). Positive (DBP-RII) and negative (DBP-RIII/IV and H (6 histidine peptide)) binding controls are also shown. c CR1 and CR2 reticulocyte binding inhibition assay using human sera (α-*P. vivax* sera). Binding percentage in both analyses were expressed as mean ± SD of three independent experiments)
Discussion
Merozoite invasion of erythrocytes involves the participation of several parasite molecules expressed at the end of the intra-erythrocyte lifecycle, mainly those contained in the apical organelles, such as the rhoptries and micronemes [8]. Only a few of these molecules possessing a reticulocyte binding role in *P. vivax* have been identified and their binding domains mapped, suggesting an urgent need for performing further studies to supplement current knowledge on *P. vivax* adhesins. This will improve our understanding of the molecular basis of parasite invasion of reticulocytes. This study aimed at using natural selection analysis for identifying GAMA functional regions playing a potential role in reticulocyte binding.

According to the phylogenetic analysis, a repeat region (RR) localised between amino acids 591 and 695 consisting of residues [A/L]AN[A/G][N/D] was predicted. This RR was common in different *P. vivax* strains but not in phylogenetically-related species (Additional file 1: Figure S1). This characteristic has been found in several *P. vivax* antigens described in the *P. vivax* VCG-I strain located on the parasite surface (Pv12 [12], ARP [43]) or in the apical pole (Pv34 [44], RON1 [45], RON2 [46] and RON4 [47, 48]). DNA sequences from different *P. vivax* strains and phylogenetically-related species were thus compared to ascertain whether *gama* gene diversity has been modulated by immune pressure. Evidence of episodic positive selection was found in some parasite lineages (Additional file 2: Figure S2). As shown for other antigens [49–51], the episodic selection found in GAMA could be the outcome of adaptation to different hosts during malaria-primate evolution [50, 51]. Therefore, the insertions found in *P. vivax* could be an adaptation of the species to humans since the RR in malaria are associated with evasion of the host’s immune response, making such response become directed against functionally unimportant regions [52, 53]. This hypothesis was supported by the fact that rPvGAMA-Ct (where the RR is located) can trigger a species-specific immune response (Fig. 2) which did not inhibit CR2 binding activity to reticulocytes (Fig. 4c).

Polymorphic regions induce high levels of strain-specific antibodies (allele specific) whilst conserved regions (directly implicated in interaction with cell receptors) are usually non-antigenic [54]. Therefore, the immune response must be directed against conserved regions to avoid different parasite strains evading immunity, thereby reducing vaccine efficacy. According to the selection signal identification strategy, low genetic diversity was found in the GAMA-encoding gene, comparable to that observed in *msp4* [55, 56], *msp7A/7 K/7 F/7 L* [57, 58], *msp8* [59], *msp10* [57, 59], *pv12, pv38* [22, 24], *pv41* [23, 24], *rap1/2* [60] and *ron4* [48] which seem involved in host cell invasion. Despite the lack of statistically significant values for dN-dS difference, Ks divergence amongst species was greater than Kn, suggesting negative selection. Many codons were found to be experiencing negative selection which probably plays an important role in GAMA evolution. Two regions along the antigen were highly conserved amongst species, giving a <0.5 evolutionary rate (ω) (Fig. 1).

Given the polymorphism and selection analysis, it was decided to determine *PvGAMA* conserved and variable region interaction with reticulocytes to validate the in silico prediction of functional regions (Figs. 3 and 4) and elucidate the protein’s function. A reticulocyte sample having a Duffy positive phenotype was used, given that *PvGAMA* reportedly has a binding role regardless of such antigen’s expression [61]. Unlike Cheng and his group, the anti-CD71 monoclonal antibody was included for identifying GAMA regions’ preference for immature reticulocyte binding as *P. vivax* merozoites have tropism for this cell type (characterised by the expression of the CD71 receptor [62]). Given that the CD71 marker is also present in activated lymphocytes, a nucleated cell depleted umbilical cord blood sample was used. The anti-CD45 was also included to totally exclude the lymphocytes from the analysis once the Wright stain revealed 0.4% of such cells (also confirmed by cytomtery analysis) (Additional file 4: Figure S4). It was also confirmed that there was no difference in reticulocyte percentage by incubating the samples for 4 and 16 h at 4°C (4 h: m ± SD = 1.24 ± 0.27; 16 h: m ± SD = 1.31 ± 0.07) (t-test: t(23) = 0.32, P > 0.777). However, it was decided to use a prolonged incubation time to enable complete protein-cell interaction.

It was found that all *PvGAMA* fragments bound to mature erythrocytes (CD71-CD45-) though to a lesser extent compared to reticulocytes (CD71 + CD45-) (Fig. 4a), thereby supporting the fact that the protein preferentially interacts with the latter cell type. The conserved fragment located in the carboxyl region (CR2) had higher reticulocyte binding than the amino one (CR1) (Fig. 4a) coinciding with that shown recently for *PvGAMA* where this fragment [F2 (aa 345 to 589) or F7 (408 to 589) regions in that study] showed higher rosetting activity, unlike the F1 region (aa 22 to 344) (amino fragment) [61]. Interestingly, CR1 and CR2 had higher CD71Kb reticulocyte binding percentages than to CD71Ko (Fig. 4b), suggesting that GAMA mainly binds to such cell type’s most immature stage. It has been reported that some reticulocytes’ integral membrane components decrease as cells mature [63]. Therefore, the findings found here suggest that *PvGAMA* receptor is less abundant in CD71Ko cells unlike CD71Kn, as a consequence of cell maturation. The fact that more than 69% of the CD71 + CD45- cells were CD71Ko (m ±
can be the explanation of why \( \text{PvGAMA} \) sequence binding to 100% of the CD71+ reticulocytes was not found (Fig. 4a). It has been observed that several \( P. \) \( \text{vivax} \) proteins, such as DBP [64], MSP-1 [16], RBP1 [14], the erythrocyte binding protein (EBP) [42], RBP1a, RBP1b [65] and RBP2 [15], have preferential reticulocyte binding activity, being the RBPAs particularly important in parasite cell selection. Taking the results obtained here into account, it can be suggested that \( P. \) \( \text{vivax} \) target cell selection is not only governed by the RBPs but other ligands are also taking place in this process, such as DBP, MSP-1, EBP and now \( \text{PvGAMA} \).

Immunoreactive proteins are considered potential candidates for developing a vaccine as it has been seen that an immune response induced during infection is related to naturally-acquired immunity [66]. Antigenicity is thus one of the classical parameters for selecting molecules when developing a vaccine. Although there was an immune response against \( \text{PvGAMA} \) (Fig. 2), this was not sufficient to inhibit the conserved regions binding to reticulocytes (Fig. 4c). It has been observed that \( P. \) \( \text{falciparum} \) proteins’ conserved regions ( implicated in target cell binding) cannot trigger an immune response when used as vaccine candidates in the \( \text{Aotus} \) model whilst non-conserved ones trigger protective responses upon parasite challenge but those are strain-specific [54]. Accordingly, the \( \text{PvGAMA} \) antibodies produced/induced during natural \( P. \) \( \text{vivax} \) infection were directed against immunodominant epitopes which are unimportant in binding activity. Bearing in mind that functional regions usually evolve more slowly and that natural negative selection tends to keep these regions conserved amongst species [25], our experimental findings suggested that CR1 and CR2 located between residues 80–320 (40% of negatively selected sites) and 514–624 (64.5% of negatively selected sites) are functionally/structurally restricted and that vaccine design should thus be focused on them.

Conclusions

To our knowledge, this study described \( \text{PvGAMA} \) reticulocyte binding properties for the first time. The \( \text{PvGAMA} \) antigenic response was principally directed against its carboxyl fragment which comprises by a repetitive region. On the other hand, it was shown that \( \text{PvGAMA} \) consists of two conserved binding fragments that bind preferentially to most immature human reticulocytes, which is consistent with the \( P. \) \( \text{vivax} \) invasion phenotype and highlights the fact that functional regions can be predicted by analysing natural selection. Further studies aimed at discerning the function of conserved regions as vaccine components are required.
Availability of data and materials
All data generated or analysed during this study are included within this article and its additional files. The pv-gamma sequence from P. vivax VCG-I strain was deposited in the GenBank database under accession number KT248546.

Authors’ contributions
LAB and DAMP devised and designed the study; LAB, DAMP, DGO, JFR and HDOs performed the experiments; LAB, DAMP, DGO and MAP analysed the results and wrote the manuscript. All authors read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Consent for publication
Not applicable.

Ethics approval and consent to participate
All individuals who participated in this research (including progenitors regarding umbilical cord samples) signed an informed consent form after receiving detailed information regarding the study’s goals. All procedures were approved by FIDIC’s ethics committee.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Molecular Biology and Immunology Department, Fundación Instituto de Inmunología de Colombia (FIDIC), Carrera 50 No. 26-20, Bogotá DC, Colombia. 2PhD Programme in Biomedical and Biological Sciences, Universidad del Rosario, Carrera 24 No. 63C-69, Bogotá DC, Colombia. 3Basic Sciences Department, School of Medicine and Health Sciences, Universidad del Rosario, Carrera 24 No. 63C-69, Bogotá DC, Colombia.

Received: 27 October 2016 Accepted: 10 May 2017
Published online: 19 May 2017

References
1. WHO. World malaria report. 2014.
2. WHO. State of the art of new vaccine research and development. 2006.
3. Patarroyo ME, Bermudez A, Patarroyo MA. Structural and immunological principles leading to chemically synthesized, multiantigenic, multistage, minimal subunit-based vaccine development. Chem Rev. 2011;111:3459–507.
4. Lanzavecchia A, Fruhwirth A, Perez L, Conti D. Antibody-guided vaccine design: identification of protective epitopes. Curr Opin Immunol. 2016;41:62–7.
5. Gardner MJ, Hall N, Fung E, White O, Berriman M, Hyman RW, et al. The multigene family nature of Plasmodium falciparum. Nature. 2002;419:498–511.
6. Bozdech Z, Llanas M, Pulliam BL, Wong ED, Zhu J, DeRei JL. The transcriptome of the in vitro erythrocytic developmental cycle of Plasmodium falciparum. PLoS Biol. 2003;1:E5.
7. Lasonder E, Ishihama Y, Andersen JS, Vermunt AM, Pain A, Sauerwein RW, et al. Genome sequence of the human malaria parasite Plasmodium falciparum. Nature. 2002;419:498–511.
8. Cowman AF, Berry D, Baum J. The cellular and molecular basis for malaria parasite invasion of the human red blood cell. J Cell Biol. 2012;198:661–71.
9. Richards JS, Beeson JG. The future for blood-stage vaccines against malaria. Immunol Cell Biol. 2009;87:377–90.
10. Arumugam KV, Taka S, Yamasaki T, Thonkukiatkul A, Miura K, Otsuki H, et al. Discovery of GAMA, a Plasmodium falciparum merozoite micronemal protein, as a novel blood-stage vaccine candidate antigen. Infect Immun. 2011;79: 4523–32.
11. Huynh VH, Camathias VB. A Toxoplasma gondii Ortho1Like Domain (OxLD) Family Gene. Plasmodium falciparum. PLoS ONE. 2016;11(2):e0148211.
12. Moynier-Folch DA, Areiza-Rojas R, Flores-Buitrago X, Silva Y, Patarroyo ME, Patarroyo MA. The GPI-anchored 6-Cys protein P12 is present in detergent-resistant microdomains of Plasmodium vivax blood stage schizonts. PLoS Negl Trop Dis. 2013;7:e2134.
13. Patarroyo MA, Calderón D, Moreno-Pérez DA. Vaccines against Plasmodium vivax: a research challenge. Expert Rev Vaccines. 2012;11:249–60.
14. Urquiza M, Patarroyo MA, Mari V, Ocampo M, Suarez J, Lopez R, et al. Identification and polymorphism of Plasmodium vivax RBP-1 peptides which bind specifically to reticulocytes. Peptides. 2002;23:2265–77.
15. Franca CT, He WQ, Gruszczynk J, Lim NT, Lin E, Kiniboro B, et al. Plasmodium vivax reticulocyte binding proteins are key targets of naturally acquired immunity in young Papua New Guinean children. PLoS Negl Trop Dis. 2016;10:e0005014.
16. Rodríguez LE, Urquiza M, Ocampo M, Curtidor H, Suarez J, Garcia J, et al. Plasmodium vivax MSP-1 peptides have high specific binding activity to human reticulocytes. Vaccine. 2002;20:1331–9.
17. Zeehman T, Tyagi RK, Tyagi K, Alam MS, Sharma YD. Host-parasite interaction: selective Pvfam-a family proteins of Plasmodium vivax bind to a restricted number of human erythrocyte receptors. J Infect Dis. 2015;211:1111–20.
18. Arevalo-Pinzon G, Bermudez M, Curtidor H, Patarroyo MA. The Plasmodium vivax rhoptry neck protein 5 is expressed in the apical pole of Plasmodium vivax VCG-1 strain schizonts and binds to human reticulocytes. Malaria J. 2015;14:106.
19. Garzon-Ospina D, Forero-Rodriguez J, Patarroyo MA. Inferring natural selection signals in Plasmodium vivax-encoded proteins having a potential role in merozoite invasion. Infect Genet Evol. 2015;33:182–8.
20. Cornejo OE, Fisher D, Escale AA. Genome-wide patterns of genetic polymorphism and signatures of selection in Plasmodium vivax. Genome Biol Evol. 2014;7:106–19.
21. Neafsey DE, Galinsky K, Jiang RH, Young L, Sykes SM, Saif S, et al. The malaria parasite Plasmodium vivax exhibits greater genetic diversity than Plasmodium falciparum. Nat Genet. 2012;44:1046–50.
22. Forero-Rodriguez J, Garzon-Ospina D, Patarroyo MA. Low genetic diversity and functional constraint in loci encoding Plasmodium vivax P12 and P38 proteins in the Colombian population. Malaria J. 2014;13:58.
23. Forero-Rodriguez J, Garzon-Ospina D, Patarroyo MA. Low genetic diversity in the locus encoding the Plasmodium vivax P41 protein in Colombia’s parasite population. Malaria J. 2014;13:388.
24. Wang Y, Ma A, Chen SB, Yang YC, Chen JH, Yin MB. Genetic diversity and natural selection of three blood-stage 6-Cys proteins in Plasmodium vivax populations from the China-Myanmar endemic border. Infect Genet Evol. 2014;28:167–74.
25. Grau D, Zheng Y, Price N, Azevedo RB, Zuñila RA, Elhaih E. On the immortality of television sets: “function” in the human genome according to the evolution-free gospel of ENCODE. Genome Biol Evol. 2015;7:578–80.
26. Escale AA, Cornejo OE, Freeland DE, Poe AC, Durrego E, Collins WE, et al. A monkey’s tale: the origin of Plasmodium vivax as a human malaria parasite. Proc Natl Acad Sci USA. 2005;102:1980–5.
27. Edgar RC. MUSCLE: multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res. 2004;32:1792–7.
28. Zhang J, Rosenberg HF, Nei M. Positive Darwinian selection after gene duplication in primate ribonuclease genes. Proc Natl Acad Sci USA. 1998;95: 3708–13.
29. Jukes THA. Evolution of protein molecules. In: Munro HN, editor. Mammalian protein metabolism. New York: Academic Press. 1969.
30. Kosakovsky Pond SL. Detecting individual sites subject to episodic diversifying selection. PLoS Genet. 2012;8:e1002764.
31. Murrell B, Wetherem JO, Moola S, Weighill T, Scheffler K, Kosakovsky Pond SL. Detecting individual sites subject to episodic diversifying selection. PLoS Genet. 2012;8:e1002764.
32. Murrell B, Moola S, Mabona A, Weighill T, Sheward D, Kosakovsky Pond SL, et al. FUBAR: a fast, unconstrained bayesian approach for inferring selection. Mol Biol Evol. 2013;30:1196–205.
33. Kosakovsky Pond SL, Posada D, Gravenor MB, Woelk CH, Frost SD. Automated phylogenetic detection of recombination using a genetic algorithm. Mol Biol Evol. 2006;23:1891–901.
34. Kosakovsky Pond SL, Murrell B, Fournier M, Frost SD, Delport W, Scheffler K. A random effects branch-site model for detecting episodic diversifying selection. Mol Biol Evol. 2011;28:3053–43.
35. Delport W, Poon AF, Frost SD, Kosakovsky Pond SL. Datamonkey 2010: a suite of phylogenetic analysis tools for evolutionary biology. Bioinformatics. 2010;26:2455–7.
36. Aurrecoechea C, Brestelli J, Brunk BP, Dommer J, Fischer S, Gajita B, et al. PlasmIDR: a functional genomic database for malaria parasites. Nucleic Acids Res. 2009;37:D359–543.
37. Moreno-Perez DA, Degano R, Ibarra N, Muro A, Patarroyo MA. Determining the Plasmodium vivax VCG-1 strain blood stage proteome. J Proteomics. 2014;13C:268–80.
38. Pico de Coana Y, Rodriguez J, Guerrero E, Barrero C, Rodriguez R, Mendoza M, et al. A highly infective Plasmodium vivax strain adapted to Astus monkeys: quantitative haematological and molecular determinations useful for F. vivax malaria vaccine development. Vaccine. 2003;21:3930–7.
39. Thompson JD, Higgins DG, Gibson TJ. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res. 1994;22:4673–80.
40. Houghten RA. General method for the rapid solid-phase synthesis of large numbers of peptides: specificity of antigen-antibody interaction at the level of individual amino acids. Proc Natl Acad Sci USA. 1985;82:5131–5.
41. Lu F, Li J, Wang B, Cheng Y, Kong DH, Cui L, et al. Profiling the humoral immune responses to Plasmodium vivax infection and identification of candidate immunogenic rhoptry-associated membrane antigen (RAMA). J Proteomics. 2014;102C:66–82.
42. Ntumngia FB, Thomson-Luque R, Torres Lde M, Gunalan K, Carvalho LH, Adams JH. A novel erythrocyte binding protein of Plasmodium vivax suggests an alternate invasion pathway into Duffy-positive reticulocytes. mBio. 2016;7:
doi: 10.1128/mBio.02195-16.
43. Moreno-Perez DA, Saldarriaga A, Patarroyo MA. Characterizing PvARP, a novel Plasmodium vivax antigen. Malaria J. 2013;12:165.
44. Mongui A, Angel DL, Gallego G, Reyes C, Martinez P, Guhl F, et al. Characterization and antigenicity of the promising vaccine candidate Plasmodium vivax 34 kDa rhoptry antigen (Pv34). Vaccine. 2009;28:415–21.
45. Moreno-Perez DA, Montenegro M, Patarroyo ME, Patarroyo MA. Identification, characterization and antigenicity of the Plasmodium vivax rhoptry neck protein 1 (PvRON1). Malaria J. 2011;10:314.
46. Arevayo-Pinzon G, Cuitrero H, Patino LC, Patarroyo MA. PvRON2, a new Plasmodium vivax rhoptry neck antigen. Malaria J. 2011;10:609.
47. Arevayo-Pinzon G, Cuitrero H, Ablrij J, Patarroyo MA. Annotation and characterization of the Plasmodium vivax rhoptry neck protein 4 (PvRON4). Malaria J. 2013;12:356.
48. Buitrago SP, Garzon-Ospina D, Patarroyo MA. Size polymorphism and low sequence diversity in the locus encoding the Plasmodium vivax rhoptry neck protein 4 (PvRON4) in Colombian isolates. Malaria J. 2016;15:501.
49. Garzon-Ospina D, Forero-Rodriguez J, Patarroyo MA. Evidence of functional divergence in MSP7 paralogous proteins: a molecular-evolutionary and phylogenetic analysis. BMC Evol Biol. 2016;16:256.
50. Muñoz-Fernández MP, Pacheco MA, Taylor JE, Prall SP, Ambu L, Nathan S, et al. Accelerated diversification of nonhuman primate malaria in Southeast Asia: adaptive radiation or geographic speciation? Mol Biol Evol. 2015;32:422–39.
51. Sawar H, Otani H, Arisue N, Palacpac N, de Oliveira ML, Pathirana S, et al. Lineage-specific positive selection at the merozoite surface protein 1 (msp1) locus of Plasmodium vivax and related simian malaria parasites. BMC Evol Biol. 2010;10:52.
52. Schofield L. On the function of repetitive domains in protein antigens of Plasmodium and other eukaryotic parasites. Parasitol Today. 1991;7:99–105.
53. Ferreira MU, da Silva NM, Wunderlich G. Antigenic diversity and immune evasion by malaria parasites. Clin Diagn Lab Immunol. 2004;11:987–95.
54. Patarroyo ME, Patarroyo MA. Emerging rules for subunit-based, multiantigenic, multistage chemically synthesized vaccines. Acc Chem Res. 2008;41:377–86.
55. Martinez P, Suarez CF, Gomez A, Cardenas PP, Guerrero JE, Patarroyo MA. High level of conservation in Plasmodium vivax merozoite surface protein 4 (PvMSP4). Infect Genet Evol. 2005;5:345–61.
56. Putnamontt C, Jongwutwisit S, Ferreira MU, Kanbara H, Udomsangphet R, Cui L. Limited global diversity of the Plasmodium vivax merozoite surface protein 4 gene. Infect Genet Evol. 2009;9:821–6.
57. Garzon-Ospina D, Romero-Murillo L, Tobon LF, Patarroyo MA. Low genetic polymorphism of merozoite surface proteins 7 and 10 in Colombian Plasmodium vivax isolates. Infect Genet Evol. 2011;11:528–31.
58. Garzon-Ospina D, Forero-Rodriguez J, Patarroyo MA. Heterogeneous genetic diversity pattern in Plasmodium vivax genes encoding merozoite surface proteins (MSP7–7E, -7F and -7L). Malaria J. 2014;13:495.
59. Pacheco MA, Elango AP, Rahman AA, Fisher D, Collins WE, Barnwell JW, et al. Evidence of purifying selection on merozoite protein 8 (MSP8) and 10 (MSP10) in Plasmodium spp. Infect Genet Evol. 2012;12:978–86.